Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2024-09-17 DOI:10.1177/10781552241285034

Wala Ben Kridis, Olfa Boudawara, Afef Khanfir

{"title":"Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study","authors":"Wala Ben Kridis, Olfa Boudawara, Afef Khanfir","doi":"10.1177/10781552241285034","DOIUrl":null,"url":null,"abstract":"ObjectiveWe aimed to evaluate the local and systemic side effects of the COVID-19 vaccine in cancer patients.Methodswe conducted a cross-sectional study including cancer patients treated at Habib Bourguiba Hospital in Sfax, Tunisia between January and March 2022. Patients should have received at least 1 dose of a COVID-19 vaccine.ResultsWe interviewed a total of 106 patients, of which 80.2% were actively treated. Mean age was 52.52. Patients were vaccinated by the Pfizer/BioNTech in 59.8% and the Oxford/AstraZeneca in 22.5%. The most frequent grade 1 or 2 adverse events occurring within 7 days were: pain at injection site (71.7%) and fatigue (38.7%). Only 2 patients developed grade 3 toxicity following vaccination. The most systemic side effects were fatigue (35.8%), fever (25.4%), headache (16.9%) and arthralgia (15.1%). They were more common after the first dose of Oxford/AstraZeneca vaccine compared to the Pfizer/BioNTech vaccine (69.6% vs 42.6%; p = 0.03). Risk of any grade toxicity (local or systemic) following the first dose was correlated with female sex (p = 0.033).ConclusionOur study showed that systemic side effects were more common after the first dose of Oxford/AstraZeneca vaccine compared to the Pfizer/BioNTech vaccine in cancer patient, with the predominance of any grade of local or systemic toxicity in women.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552241285034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectiveWe aimed to evaluate the local and systemic side effects of the COVID-19 vaccine in cancer patients.Methodswe conducted a cross-sectional study including cancer patients treated at Habib Bourguiba Hospital in Sfax, Tunisia between January and March 2022. Patients should have received at least 1 dose of a COVID-19 vaccine.ResultsWe interviewed a total of 106 patients, of which 80.2% were actively treated. Mean age was 52.52. Patients were vaccinated by the Pfizer/BioNTech in 59.8% and the Oxford/AstraZeneca in 22.5%. The most frequent grade 1 or 2 adverse events occurring within 7 days were: pain at injection site (71.7%) and fatigue (38.7%). Only 2 patients developed grade 3 toxicity following vaccination. The most systemic side effects were fatigue (35.8%), fever (25.4%), headache (16.9%) and arthralgia (15.1%). They were more common after the first dose of Oxford/AstraZeneca vaccine compared to the Pfizer/BioNTech vaccine (69.6% vs 42.6%; p = 0.03). Risk of any grade toxicity (local or systemic) following the first dose was correlated with female sex (p = 0.033).ConclusionOur study showed that systemic side effects were more common after the first dose of Oxford/AstraZeneca vaccine compared to the Pfizer/BioNTech vaccine in cancer patient, with the predominance of any grade of local or systemic toxicity in women.

查看原文本刊更多论文

突尼斯癌症患者接种 COVID-19 疫苗后产生的局部和全身副作用：前瞻性单中心研究

方法我们开展了一项横断面研究，研究对象包括2022年1月至3月期间在突尼斯斯法克斯哈比卜-布尔吉巴医院接受治疗的癌症患者。结果我们共访问了 106 名患者，其中 80.2% 正在接受治疗。平均年龄为 52.52 岁。59.8%的患者在辉瑞/BioNTech公司接种了疫苗，22.5%的患者在牛津/阿斯利康公司接种了疫苗。7天内最常发生的1级或2级不良反应是：注射部位疼痛（71.7%）和疲劳（38.7%）。只有 2 名患者在接种疫苗后出现了 3 级毒性反应。最常见的全身性副作用是疲劳（35.8%）、发热（25.4%）、头痛（16.9%）和关节痛（15.1%）。与辉瑞/BioNTech疫苗相比，牛津/阿斯利康疫苗首剂后的副作用更常见（69.6% 对 42.6%；P = 0.03）。结论我们的研究表明，与辉瑞/生物技术疫苗相比，牛津/阿斯利康疫苗在癌症患者首次接种后更容易出现全身副作用，其中女性患者更容易出现任何程度的局部或全身毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...